Please find attached Consolidated & Standalone Financial Results for the quarter and half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 1.3 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Titan Biotech reported strong Q2 FY26 results with standalone revenue from operations of Rs. 5,435.47 lakhs, up about 36% YoY from Rs. 3,989.11 lakhs. Standalone profit after tax rose to Rs. 686.25 lakhs versus Rs. 500.35 lakhs, a roughly 37% YoY jump, taking EPS for the quarter to Rs. 8.30. For the half year (H1 FY26), standalone revenue grew about 21.5% to Rs. 10,085.11 lakhs and PAT grew about 21.7% to Rs. 1,302.33 lakhs. On a consolidated basis, Q2 PAT was Rs. 764.72 lakhs (including Rs. 78.47 lakhs share from associates Peptech Biosciences and Titan Media), while H1 consolidated PAT was Rs. 1,462.75 lakhs. The statutory auditor, A N S K & Associates, issued a clean limited review report with no qualifications. Operating cash flow stayed healthy at Rs. 1,105.69 lakhs for H1, and an interim dividend of Rs. 165.27 lakhs was paid.
Sharp double-digit revenue and profit growth, combined with a clean auditor review and positive operating cash flows, point to continued operational momentum and no immediate governance red flags for shareholders.